Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Royalty Pharma Plc's Business Segments
Royalty Pharma Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Financial Royalty Assets
Total Revenue
$ 674
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Financial Royalty Assets0%
- Royalty Income, Other10.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Financial Royalty Assets | $ 1,233 | - |
| Royalty Income, Other | $ 72 | 10.6% |
Revenue by Product & Service Category - FY
- Financial Royalty Assets94.4%
- Royalty Income, Other5.6%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Financial Royalty Assets | $ 595 | 94.4% |
| Royalty Income, Other | $ 36 | 5.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Financial Royalty Assets0%
- Royalty Income, Other10.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Financial Royalty Assets | $ 1,233 | - |
| Royalty Income, Other | $ 72 | 10.6% |
Description of Royalty Pharma Plc
Royalty Pharma Plc is a pharmaceutical company that specializes in acquiring and managing royalty interests in innovative biopharmaceutical products. Established in 1996, the company has since grown to become the largest buyer of biopharmaceutical royalties in the world.
As a business model, Royalty Pharma does not engage in the research, development, or commercialization of new drugs. Instead, the company acquires the rights to receive future royalties from the sale of existing therapies. In doing so, it provides a valuable source of financing for drug developers and manufacturers, while also generating revenue through the collection of these royalties.
The company's portfolio includes approximately 50 different products that are sold around the world. These products are primarily used in the treatment of cancer, immunological disorders, infectious diseases, and rare genetic disorders. Some of the notable products in the Royalty Pharma portfolio include the cancer drug Imbruvica, the HIV therapy Prezcobix, and the cystic fibrosis treatment Kalydeco.
Aside from acquiring and managing royalty interests, Royalty Pharma also invests in the development of new therapies. The company partners with pharmaceutical companies and academic institutions to fund research and development programs that may lead to new, innovative treatments. Thus, Royalty Pharma is a key contributor to the advancement of modern medicine.
Royalty Pharma is headquartered in New York City and has additional offices in London, Dublin, and Jersey City. The company went public in June 2020 and is currently listed on the NASDAQ Stock Exchange under the ticker symbol RPRX. With a market capitalization of over $30 billion, Royalty Pharma is considered one of the largest and most successful pharmaceutical companies in the world.
As a business model, Royalty Pharma does not engage in the research, development, or commercialization of new drugs. Instead, the company acquires the rights to receive future royalties from the sale of existing therapies. In doing so, it provides a valuable source of financing for drug developers and manufacturers, while also generating revenue through the collection of these royalties.
The company's portfolio includes approximately 50 different products that are sold around the world. These products are primarily used in the treatment of cancer, immunological disorders, infectious diseases, and rare genetic disorders. Some of the notable products in the Royalty Pharma portfolio include the cancer drug Imbruvica, the HIV therapy Prezcobix, and the cystic fibrosis treatment Kalydeco.
Aside from acquiring and managing royalty interests, Royalty Pharma also invests in the development of new therapies. The company partners with pharmaceutical companies and academic institutions to fund research and development programs that may lead to new, innovative treatments. Thus, Royalty Pharma is a key contributor to the advancement of modern medicine.
Royalty Pharma is headquartered in New York City and has additional offices in London, Dublin, and Jersey City. The company went public in June 2020 and is currently listed on the NASDAQ Stock Exchange under the ticker symbol RPRX. With a market capitalization of over $30 billion, Royalty Pharma is considered one of the largest and most successful pharmaceutical companies in the world.
Royalty Pharma Plc, a prominent player in the healthcare investment sector, specializes in acquiring and managing royalty interests related to pharmaceutical and biotech products. The company has established a diverse portfolio that capitalizes on the rapid advancements and innovative treatments emerging in the healthcare landscape, primarily focusing on therapeutic areas such as oncology, HIV/AIDS, neuroscience, cardiovascular diseases, and orphan drugs. Below is a detailed exploration of the company’s segments, product categories, and services.
Segments
Royalty Pharma operates primarily through two business segments:
1. Royalty Interests:
This segment is the backbone of Royalty Pharmas operations, where the company strategically acquires royalty interests associated with pharmaceutical and biotech products that are either in development or already in the market.
- Structure of Royalties: The royalties are typically structured as a percentage of the net sales generated by these drugs, allowing Royalty Pharma to benefit financially without bearing the costs associated with the development, marketing, or commercialization of the products. This model minimizes financial exposure while maximizing potential revenue streams from successful therapies.
- Focus on Innovation: By acquiring interests in innovative products, Royalty Pharma positions itself to gain from advancing medical technologies and therapies, ensuring a steady flow of revenue from successful drugs.
2. Financial Assets:
This segment encompasses a range of investments made by Royalty Pharma, including publicly traded securities, royalty notes, and various other financial instruments.
- Investment Strategy: The financial assets segment is designed to generate interest earnings, enhance liquidity, and diversify the overall investment portfolio. This approach helps stabilize revenue flows even if the royalty segment faces fluctuations in performance or market dynamics.
Products and Services
Royalty Pharmas offerings are categorized based on the therapeutic areas of the drugs in which it holds royalty interests. The primary categories include:
1. Oncology:
- Royalty Pharma holds an extensive portfolio of royalties from leading-edge cancer therapies. These drugs target various forms of cancer, including lung cancer, breast cancer, prostate cancer, and hematologic cancers (blood cancers). The emphasis on oncology reflects the growing need for effective cancer treatments, spurred by the rising incidence of cancer globally.
2. HIV/AIDS:
- In the realm of infectious diseases, Royalty Pharma has vested interests in several groundbreaking treatments for HIV/AIDS. The drugs focus on lowering the viral load in patients and have shown efficacy in delaying the progression of the disease, which is critical in managing chronic conditions such as HIV.
3. Neuroscience:
- The companys investments in neuroscience include royalty interests in pharmaceutical products that address neurological disorders, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. The focus on these debilitating conditions highlights Royalty Pharmas commitment to improving neurological health and enhancing the quality of life for affected individuals.
4. Cardiovascular:
- Royalty Pharma has also secured royalties related to cardiovascular drugs, which are essential in managing conditions like hypertension and heart failure. Given the high prevalence of cardiovascular diseases, Royalty Pharma’s interests in this area respond to a crucial public health need.
5. Orphan Drugs:
- Royalty Pharma recognizes the importance of rare diseases and holds royalties for several orphan drugs designed to treat conditions that affect smaller populations—specifically, diseases impacting fewer than 200,000 individuals in the United States. This segment aligns with broader healthcare goals to ensure that patients with rare diseases receive access to effective therapies.
6. Royalty Financing:
- Beyond acquiring royalty interests, Royalty Pharma offers royalty financing solutions to pharmaceutical and biotech companies. This type of financing involves providing non-dilutive funding to these companies, which is structured based on the projected revenues of their products. By enabling companies to secure necessary capital without equity dilution, Royalty Pharma fosters innovation and development within the industry.
Conclusion
Royalty Pharma Plc has established itself as a key player in the healthcare investment space by focusing on acquiring and managing royalty interests in pharmaceutical and biotech products. With a diverse portfolio of royalties spanning critical therapeutic areas, the company not only ensures a robust revenue-generating mechanism but also contributes to the advancement of medical treatments and therapies. Additionally, through royalty financing, Royalty Pharma bolsters the growth trajectories of its partner companies, ultimately enriching the pharmaceutical landscape and enhancing patient outcomes across various healthcare segments.
Segments
Royalty Pharma operates primarily through two business segments:
1. Royalty Interests:
This segment is the backbone of Royalty Pharmas operations, where the company strategically acquires royalty interests associated with pharmaceutical and biotech products that are either in development or already in the market.
- Structure of Royalties: The royalties are typically structured as a percentage of the net sales generated by these drugs, allowing Royalty Pharma to benefit financially without bearing the costs associated with the development, marketing, or commercialization of the products. This model minimizes financial exposure while maximizing potential revenue streams from successful therapies.
- Focus on Innovation: By acquiring interests in innovative products, Royalty Pharma positions itself to gain from advancing medical technologies and therapies, ensuring a steady flow of revenue from successful drugs.
2. Financial Assets:
This segment encompasses a range of investments made by Royalty Pharma, including publicly traded securities, royalty notes, and various other financial instruments.
- Investment Strategy: The financial assets segment is designed to generate interest earnings, enhance liquidity, and diversify the overall investment portfolio. This approach helps stabilize revenue flows even if the royalty segment faces fluctuations in performance or market dynamics.
Products and Services
Royalty Pharmas offerings are categorized based on the therapeutic areas of the drugs in which it holds royalty interests. The primary categories include:
1. Oncology:
- Royalty Pharma holds an extensive portfolio of royalties from leading-edge cancer therapies. These drugs target various forms of cancer, including lung cancer, breast cancer, prostate cancer, and hematologic cancers (blood cancers). The emphasis on oncology reflects the growing need for effective cancer treatments, spurred by the rising incidence of cancer globally.
2. HIV/AIDS:
- In the realm of infectious diseases, Royalty Pharma has vested interests in several groundbreaking treatments for HIV/AIDS. The drugs focus on lowering the viral load in patients and have shown efficacy in delaying the progression of the disease, which is critical in managing chronic conditions such as HIV.
3. Neuroscience:
- The companys investments in neuroscience include royalty interests in pharmaceutical products that address neurological disorders, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. The focus on these debilitating conditions highlights Royalty Pharmas commitment to improving neurological health and enhancing the quality of life for affected individuals.
4. Cardiovascular:
- Royalty Pharma has also secured royalties related to cardiovascular drugs, which are essential in managing conditions like hypertension and heart failure. Given the high prevalence of cardiovascular diseases, Royalty Pharma’s interests in this area respond to a crucial public health need.
5. Orphan Drugs:
- Royalty Pharma recognizes the importance of rare diseases and holds royalties for several orphan drugs designed to treat conditions that affect smaller populations—specifically, diseases impacting fewer than 200,000 individuals in the United States. This segment aligns with broader healthcare goals to ensure that patients with rare diseases receive access to effective therapies.
6. Royalty Financing:
- Beyond acquiring royalty interests, Royalty Pharma offers royalty financing solutions to pharmaceutical and biotech companies. This type of financing involves providing non-dilutive funding to these companies, which is structured based on the projected revenues of their products. By enabling companies to secure necessary capital without equity dilution, Royalty Pharma fosters innovation and development within the industry.
Conclusion
Royalty Pharma Plc has established itself as a key player in the healthcare investment space by focusing on acquiring and managing royalty interests in pharmaceutical and biotech products. With a diverse portfolio of royalties spanning critical therapeutic areas, the company not only ensures a robust revenue-generating mechanism but also contributes to the advancement of medical treatments and therapies. Additionally, through royalty financing, Royalty Pharma bolsters the growth trajectories of its partner companies, ultimately enriching the pharmaceutical landscape and enhancing patient outcomes across various healthcare segments.